Literature DB >> 11161123

Somatization: a debilitating syndrome in primary care.

L A Allen1, M A Gara, J I Escobar, H Waitzkin, R C Silver.   

Abstract

Somatization is a significant problem for clinical medicine. Unlike somatization disorder, which is relatively rare, abridged somatization, a less severe form of somatization, is prevalent in primary care clinics. The authors examined the clinical status and functioning of patients diagnosed with a depression or anxiety disorder comorbid with abridged somatization and compared them with patients diagnosed with a depression or anxiety disorder alone. The authors examined severity of physical functioning and psychopathology in relation to diagnostic status. Patients diagnosed with both abridged somatization and a depression or anxiety disorder were more physically impaired and more anxious than those diagnosed with a depression or anxiety disorder alone. The results suggest that abridged somatization frequently coexists with depression and anxiety and thus complicates the presentation of these disorders.

Entities:  

Mesh:

Year:  2001        PMID: 11161123     DOI: 10.1176/appi.psy.42.1.63

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  12 in total

1.  The cost of somatisation among the working-age population in England for the year 2008-2009.

Authors:  Sarah L Bermingham; Alan Cohen; John Hague; Michael Parsonage
Journal:  Ment Health Fam Med       Date:  2010-06

2.  Cultural differences in the experience of everyday symptoms: a comparative study of South Asian and European American women.

Authors:  Alison Karasz; Kara Dempsey; Ronit Fallek
Journal:  Cult Med Psychiatry       Date:  2007-12

Review 3.  Somatoform disorders and medically unexplained symptoms in primary care.

Authors:  Heidemarie Haller; Holger Cramer; Romy Lauche; Gustav Dobos
Journal:  Dtsch Arztebl Int       Date:  2015-04-17       Impact factor: 5.594

4.  Whether medically unexplained or not, three or more concurrent somatic symptoms predict psychopathology and service use in community populations.

Authors:  Javier I Escobar; Benjamin Cook; Chi-Nan Chen; Michael A Gara; Margarita Alegría; Alejandro Interian; Esperanza Diaz
Journal:  J Psychosom Res       Date:  2010-02-16       Impact factor: 3.006

5.  The level of recognition of physical symptoms in patients with a major depression episode in the outpatient psychiatric practice in Puerto Rico: an observational study.

Authors:  Jorge M Tamayo; Karis Román; Juan J Fumero; María Rivas
Journal:  BMC Psychiatry       Date:  2005-06-20       Impact factor: 3.630

6.  Does simple "reassurance" work in patients with medically unexplained physical symptoms?

Authors:  Javier I Escobar
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

7.  Medically unexplained and explained physical symptoms in the general population: association with prevalent and incident mental disorders.

Authors:  Jonna van Eck van der Sluijs; Margreet Ten Have; Cees Rijnders; Harm van Marwijk; Ron de Graaf; Christina van der Feltz-Cornelis
Journal:  PLoS One       Date:  2015-04-08       Impact factor: 3.240

8.  25 Hydroxyvitamin D levels, quality of life, and disability in long-standing patients of somatization.

Authors:  Shruti Srivastava; Manjeet Singh Bhatia; Priyanka Gautam
Journal:  Ind Psychiatry J       Date:  2018 Jan-Jun

9.  Insurance-Reimbursable Mindfulness for Safety-Net Primary Care Patients: A Pilot Randomized Controlled Trial.

Authors:  Richa Gawande; Elizabeth Pine; Todd Griswold; Timothy Creedon; Zayda Vallejo; Elana Rosenbaum; Angela Lozada; Zev Schuman-Olivier
Journal:  Mindfulness (N Y)       Date:  2019-03-18

10.  Cognitive-behaviour therapy for patients with Abridged Somatization Disorder (SSI 4,6) in primary care: a randomized, controlled study.

Authors:  Rosa Magallón; Margalida Gili; Sergio Moreno; Natalia Bauzá; Javier García-Campayo; Miquel Roca; Yolanda Ruiz; Eva Andrés
Journal:  BMC Psychiatry       Date:  2008-06-22       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.